Gain Therapeutics (GANX) Debt to Equity (2020 - 2025)
Gain Therapeutics (GANX) has 6 years of Debt to Equity data on record, last reported at $0.07 in Q3 2025.
- For Q3 2025, Debt to Equity rose 29.4% year-over-year to $0.07; the TTM value through Sep 2025 reached $0.07, up 29.4%, while the annual FY2024 figure was $0.06, 32.34% up from the prior year.
- Debt to Equity reached $0.07 in Q3 2025 per GANX's latest filing, down from $0.12 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.12 in Q2 2025 and bottomed at $0.02 in Q1 2021.
- Average Debt to Equity over 5 years is $0.05, with a median of $0.04 recorded in 2024.
- Peak YoY movement for Debt to Equity: tumbled 83.25% in 2021, then soared 195.95% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.02 in 2021, then surged by 60.27% to $0.03 in 2022, then soared by 41.26% to $0.05 in 2023, then surged by 32.34% to $0.06 in 2024, then increased by 20.19% to $0.07 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.07 in Q3 2025, $0.12 in Q2 2025, and $0.07 in Q1 2025.